Rubicon Research Limited

Rubicon Research Limited

Rubicon Research Limited has filed a scheme of merger of its wholly owned subsidiary, Kia Health Tech Private Limited, with the company, subject to regulatory approvals and stakeholder consent.

Rubicon Research Limited

Rubicon Research Limited has acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC for USD 2.9 million. The facility will focus on Rubicon's specialty and high-value products as well as demand from US government departments. The company expects to commence manufacturing at the site in calendar year 2027 after completing implementation of its quality management systems.

Rubicon Research Limited

Rubicon Research Limited has announced the record date for the purpose of dividend payment as August 7, 2026, and also updated on the merger of Kia Health Tech Private Limited with the company.

Rubicon Research Limited

Rubicon Research Limited has informed the Exchange regarding Outcome of Board Meeting held on July 20, 2026. The Board of Directors has approved the date of 27th Annual General Meeting and Record Date for payment of final dividend on equity shares for the financial year 2025-26. The company has also updated on the merger of Kia Health Tech Private Limited, a wholly owned subsidiary, with Rubicon Research Limited.

Rubicon Research Limited

Rubicon Research Limited has informed the Exchange regarding the allotment of 1,49,158 fully paid-up equity shares of INR 1 each, pursuant to exercise of employee stock options under the Rubicon Research Limited - Employee Stock Option Scheme 2022.

Rubicon Research Limited

Rubicon Research Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended June 30, 2026.

Rubicon Research Limited

Rubicon Research Limited has informed the Exchange about a US FDA inspection of its manufacturing facility in Pithampur, Madhya Pradesh. The inspection was unannounced and resulted in a Form 483 with 2 procedural observations. The company is confident of working with the regulator to resolve the issues.

Rubicon Research Limited

Rubicon Research Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, due to the declaration of Unaudited Financial Results for the quarter and year ending June 30, 2026.

Rubicon Research Limited

Rubicon Research Limited has filed a disclosure with the NSE under Regulations 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing relates to the mandatory annual disclosure by promoters concerning any encumbrances, such as pledged shares, on their holdings. While the announcement does not detail specific financial figures, it signifies the company's compliance with crucial transparency requirements. For investors, such disclosures are important for assessing promoter financial health and potential risks associated with pledged shares, which can influence market perception and stock stability.